Compare Raymond James Financial, Inc. (RJF) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs Revvity Inc — how do they compare? Raymond James Financial, Inc. trades at $159.21 (market cap $30.51B), while Revvity Inc trades at $155.18 (market cap $16.98B). The key difference: Raymond James Financial, Inc. is the larger of the two by market cap, and Raymond James Financial, Inc. pays the higher dividend (1.36%). Which is the better fit depends on your goals — on Pluang, investors hold Raymond James Financial, Inc. for 75 Days and Revvity Inc for 12 Days on average.
| RJF | RVTY | |
|---|---|---|
Market Cap | $30.51B | $16.98B |
Volume | 1,206,253 | 1,456,900 |
Sector | Financials | Health |
52-Week High | $181.18 | $157.36 |
52-Week Low | $140.89 | $82.26 |
Typical Hold Time | 75 Days | 12 Days |
Enterprise Value | $24.37B | $19.30B |
Dividend Yield | 1.36% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Raymond James Financial (RJF) trades at $159.04, up 1.11% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.14 surpassing the $2.93 estimate. Revenue has grown steadily from $10.9B in 2022 to $13.84B in 2025, while net income reached $2.14B. A quarterly dividend of $0.54 was declared, payable in October 2026.
The outlook is supported by solid fundamentals, including a P/E of 13.83 and ROE of 18.48%, but risks include volatile cash flows from investing activities and rising expenses. Analysts are neutral with a consensus price target of $184.00, implying potential upside. Investor sentiment is mixed amid recent institutional buying and selling activity.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
